ExcellaBio LLC   Report issue

For profit Phase 2
Founded: New York NY United States (2017)

Organization Overview

First Clinical Trial
2017
NCT03342417
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

ExcellaBio LLC

Active Ingredients

Drugs in Phase 2 Trials (2)

ipilimumab (yervoy) (1 trial)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Ovarian Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2